Literature DB >> 32533674

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy.

Luis Margusino-Framiñán1, Aitziber Illarro-Uranga2, Karina Lorenzo-Lorenzo3, Emilio Monte-Boquet4, Esther Márquez-Saavedra5, Noelia Fernández-Bargiela1, David Gómez-Gómez2, Natividad Lago-Rivero3, José Luis Poveda-Andrés4, Rocío Díaz-Acedo5, Juan Luis Hurtado-Bouza1, Julia Sánchez-Gundín2, Cristina Casanova-Martínez3, Ramón Morillo-Verdugo5.   

Abstract

Hospital Pharmacy Service (HPS) in Spain have been impacted by the health  crisis caused by the COVID-19 pandemic. Thus, the outbreak has forced HPSs to adapt their outpatient consultation services to Telepharmacy to optimize clinical  outcomes and reduce the risk of contagion. The purpose of this article is to  describe and analyze the experience of HPSs with outpatient Telepharmacy  during the COVID-19 pandemic and expose the lessons learned. Measures have  been adopted in on-site outpatient pharmacy clinics to prevent exposure of  patients and professionals to the virus. These measures are based on national  and international recommendations on social distancing and hygiene. With  regard to remote outpatient pharmacy services, teleconsultation with drug  dispensing has been promoted based on five basic procedures, each with its  advantages and limitations: home drug delivery from HPSs, with the advantage  of universal access and the limitation of entailing a substantial investment in  resources; HPS coordination with primary care pharmacists, which requires no  investments but with limited access to some geographic areas; HPS coordination with community pharmacists based on a large network of pharmacies, which  requires the patient to go to the pharmacy, without confidentiality being  guaranteed for any patient; geolocation and hospital-based medication  dispensing, which provides universal access and direct traceability, but entails  investment in human resources; and HPS coordination with associations of  patients, which does not entail any additional cost but limits the information  available on the diseases of society members. Three main lessons have been learned during the pandemic: the satisfactory capacity of HPS to provide outpatient pharmacy consultation services in the setting of a public health crisis; the usefulness of Telepharmacy for the clinical follow-up, healthcare coordination, outpatient counseling, and informed dispensing and delivery of  medication (with a high level of satisfaction among patients); and the need to  foster Telepharmacy as a complementary tool through a mixed model of  outpatient pharmacy consultation service that incorporates the advantages of  each procedure and adapts to the individual needs of each patient in a context of humanized healthcare. Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32533674     DOI: 10.7399/fh.11498

Source DB:  PubMed          Journal:  Farm Hosp        ISSN: 1130-6343


  10 in total

1.  Pharmacists' Perspectives on the Use of Telepharmacy in Response to COVID-19 Pandemic in Ho Chi Minh City, Vietnam.

Authors:  Truong Van Dat; Trung Dinh Tran; Nguyen Thao My; Tran Thi Hong Nguyen; Nguyen Nhat Anh Quang; Mi Tra Vo Nguyen; Phuc Hong Ngoc Vo; Thanh-Tam Ho; Cuong Manh Nguyen; Tram Thi Ngoc Nguyen; Nguyen-Huu Lac-Thuy; Nga Tq Nguyen; Dieu-Thuong Thi Trinh; Hai-Yen Nguyen-Thi; Nguyen Tien Huy
Journal:  J Pharm Technol       Date:  2022-02-25

2.  Exploring the perception and readiness of Pharmacists towards telepharmacy implementation; a cross sectional analysis.

Authors:  Khayal Muhammad; Mohamed A Baraka; Syed Sikandar Shah; Muhammad Hammad Butt; Haytham Wali; Muhammad Saqlain; Tauqeer Hussain Mallhi; Khezar Hayat; Khairi Mustafa Fahelelbom; Royes Joseph; Yusra Habib Khan
Journal:  PeerJ       Date:  2022-05-25       Impact factor: 3.061

Review 3.  Expanded roles of community pharmacists in COVID-19: A scoping literature review.

Authors:  Tanapong Pantasri
Journal:  J Am Pharm Assoc (2003)       Date:  2021-12-24

Review 4.  Overview of Technologies Implemented During the First Wave of the COVID-19 Pandemic: Scoping Review.

Authors:  Alaa Abd-Alrazaq; Asmaa Hassan; Israa Abuelezz; Arfan Ahmed; Mahmood Saleh Alzubaidi; Uzair Shah; Dari Alhuwail; Anna Giannicchi; Mowafa Househ
Journal:  J Med Internet Res       Date:  2021-09-14       Impact factor: 5.428

5.  Outpatients' Opinion And Experience Regarding Telepharmacy During The COVID-19 Pandemic: The Enopex Project.

Authors:  Luis Margusino-Framiñán; Cecilia M Fernández-Llamazares; Eva Negro-Vega; Begoña Tortajada-Goitia; Garbiñe Lizeaga; Gabriel Mercadal-Orfila; Carmen Almeida-González; Ramón Morillo-Verdugo
Journal:  J Multidiscip Healthc       Date:  2021-12-31

6.  Exploring the Pharmaceutical Care of Pharmacists in China During COVID-19-A National Multicenter Qualitative Study.

Authors:  Mingxia Wang; Zhao Yin; Wan Zhang; Xuedong Jia; Shuzhang Du; Jun Li; Xiaojian Zhang
Journal:  Front Public Health       Date:  2022-01-27

7.  Survey of the patients' perspectives and preferences in adopting telepharmacy versus in-person visits to the pharmacy: a feasibility study during the COVID-19 pandemic.

Authors:  Khadijeh Moulaei; Mostafa Shanbehzadeh; Kambiz Bahaadinbeigy; Hadi Kazemi-Arpanahi
Journal:  BMC Med Inform Decis Mak       Date:  2022-04-13       Impact factor: 2.796

Review 8.  Healthcare Professionals' Experience of Performing Digital Care Visits-A Scoping Review.

Authors:  Ieva Lampickienė; Nadia Davoody
Journal:  Life (Basel)       Date:  2022-06-17

Review 9.  COVID the Catalyst for Evolving Professional Role Identity? A Scoping Review of Global Pharmacists' Roles and Services as a Response to the COVID-19 Pandemic.

Authors:  Kaitlyn E Watson; Theresa J Schindel; Marina E Barsoum; Janice Y Kung
Journal:  Pharmacy (Basel)       Date:  2021-05-04

10.  An emergency plan for management of COVID-19 patients in rural areas.

Authors:  Ahmad Z Al Meslamani; Amira B Kassem; Noha A El-Bassiouny; Osama Mohamed Ibrahim
Journal:  Int J Clin Pract       Date:  2021-07-05       Impact factor: 3.149

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.